Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class.
Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class.
The announcement follows a …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Regeneron immunotherapy combo comes up short in melanoma trial
Why Is Regeneron Stock Sinking Monday? - Regeneron Pharmaceuticals (NASDAQ:REGN)
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
FDA Blocked Melanoma Drug as Confusion Reigned Under Makary - KFF Health News
Amplia takes aim at billion-dollar pancreatic cancer drug market
BioMarin drug acquired in buyout misses goal in rare disease study
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study
FDA blocked melanoma drug as confusion reigned under Makary
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding…
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a…
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose…
Pfizer and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals.
US regulators are willing to reconsider using a Phase 3 study of tab-cel as the basis for an approval, after previously rejecting…
An experimental antibody-drug conjugate from Merck and Kelun-Biotech succeeded in a global Phase 3 study for the first time,…
